Skip Navigation

Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLAA02:01-positive Participants with Previously Treated Advanced Melanoma TEBE-AM

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT05549297

Study #:
STUDY00161234

Start Date:
Apr 24, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05549297

View Complete Trial Details & Eligibility at ClinicalTrials.gov